• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Correction to: Nonacog Beta Pegol: A Review in Haemophilia B.对《重组人凝血因子IX聚乙二醇化修饰物:B型血友病综述》的更正
Drugs. 2018 Jul;78(11):1169. doi: 10.1007/s40265-018-0951-1.
2
Correction to: Lonoctocog Alfa: A Review in Haemophilia A.对《重组人凝血因子VIII:A型血友病综述》的更正
Drugs. 2018 Mar;78(4):521. doi: 10.1007/s40265-018-0886-6.
3
Correction to: GP2015: An Etanercept Biosimilar.对《GP2015:一种依那西普生物类似药》的勘误
BioDrugs. 2018 Oct;32(5):525. doi: 10.1007/s40259-018-0296-z.
4
Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.对《2型糖尿病中的胰高血糖素样肽-1受体激动剂:它们的用途及差异特征》的勘误
Clin Drug Investig. 2019 Oct;39(10):1019. doi: 10.1007/s40261-019-00852-y.
5
Correction to: Migalastat: A Review in Fabry Disease.对《米加司他:法布里病综述》的更正
Drugs. 2019 Aug;79(12):1363. doi: 10.1007/s40265-019-01166-1.
6
Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.对《比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺:HIV-1感染综述》的勘误
Drugs. 2019 Apr;79(6):687. doi: 10.1007/s40265-019-01101-4.
7
Correction to: Tocilizumab: A Review in Rheumatoid Arthritis.对《托珠单抗:类风湿关节炎综述》的更正
Drugs. 2018 Feb;78(2):285. doi: 10.1007/s40265-017-0856-4.
8
Correction to: Revefenacin: First Global Approval.对《瑞芬太尼:首次全球获批》的更正
Drugs. 2019 Apr;79(6):689. doi: 10.1007/s40265-019-01106-z.
9
Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.对《A型肉毒毒素:预防慢性偏头痛的综述》的更正
Drugs. 2018 Apr;78(6):715. doi: 10.1007/s40265-018-0906-6.
10
Correction to: Ubrogepant: First Approval.更正:ubrogepant:首次批准。
Drugs. 2020 Apr;80(5):523. doi: 10.1007/s40265-020-01292-1.

引用本文的文献

1
Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design.生物制药的药代动力学:它们在分子设计中的关键作用。
Biomedicines. 2023 May 16;11(5):1456. doi: 10.3390/biomedicines11051456.

对《重组人凝血因子IX聚乙二醇化修饰物:B型血友病综述》的更正

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B.

作者信息

Syed Yahiya Y

机构信息

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

出版信息

Drugs. 2018 Jul;78(11):1169. doi: 10.1007/s40265-018-0951-1.

DOI:10.1007/s40265-018-0951-1
PMID:30003467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6061402/
Abstract

The article Nonacog Beta Pegol: A Review in Haemophilia B, written by Yahiya Y. Syed, was originally published Online First without open access. After publication in volume 77, issue 18, pages 2003-2012 Novo Nordisk A/S requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Novo Nordisk A/S. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

摘要

由亚希亚·Y·赛义德撰写的《重组凝血因子IX聚乙二醇修饰物:B型血友病综述》一文最初以优先在线发表形式发布,无开放获取权限。在第77卷第18期第2003 - 2012页发表后,诺和诺德公司要求将该文章设为开放选择,以使文章成为开放获取出版物。出版后开放获取由诺和诺德公司资助。该文章随即根据知识共享署名 - 非商业性使用4.0国际许可协议(http://creativecommons.org/licenses/by-nc/4.0/)进行分发,该协议允许在任何媒介或格式下进行任何非商业性使用、复制、改编、分发和复制,只要您适当引用原始作者和来源、提供知识共享许可协议的链接并表明是否做了更改。